When one insider sells, it's a tax bill. When the entire C-suite sells at the same time, it's a warning flare. Over the past two weeks, Royal Caribbean's executive team has unloaded a staggering $166 million worth of stock. The CEO sold 7,854 shares. The CFO dumped 51,131 shares. Two directors collectively sold 281,385 shares. The chief accounting officer and two other executives also hit the sell button. At over $300 per share, the numbers add up fast — and the coordinated nature of the selling is hard to ignore. This isn't routine portfolio rebalancing. Royal Caribbean insiders didn't sell...

In a market getting pummeled by tariff anxiety and tech selloffs, Domino's Pizza did something radical on Monday: it went up. Shares surged 6% after the pizza giant dropped a Q4 earnings report that showed exactly what Wall Street wanted to see — growth, cash flow, and a fat dividend hike. Revenue hit $1.54 billion, up 6.4% year over year and topping the $1.52 billion consensus estimate. U.S. same-store sales grew 3.7%, beating the 3.47% analysts had penciled in. The only blemish was a tiny EPS miss — $5.35 versus $5.39 expected. Nobody cared. The real headline was the dividend. Domino's Boa...

Just days after CEO Daniel O'Day told investors M&A wasn't an urgent priority, Gilead Sciences dropped $7.8 billion to gobble up Arcellx — the biotech partner it's been courting since 2022. The deal pays Arcellx shareholders $115 per share in cash, a 79% premium to Friday's close. Shares of Arcellx rocketed 78% on the news Monday morning. Gilead dipped about 1%. Classic acquirer-target dynamic — the buyer always bleeds a little. The prize is anito-cel, an investigational CAR-T cell therapy targeting multiple myeloma, one of the most common and deadly blood cancers. CAR-T works by reprogr...

Remember when building anything in America took longer than a Marvel movie franchise? Well, plot twist: the government just hit the fast-forward button, but only for their favorite kids. While everyone was arguing about politics on Twitter, something way more important was happening in the basement of bureaucracy. The feds basically said "screw the red tape" when it comes to AI infrastructure. They're calling it the "One Rule" economy, and honestly, it's the biggest policy shift since someone decided the internet was kind of important. Here's the deal: For decades, if you wanted to build lit...

Remember when your biggest career worry was whether robots would steal factory jobs? Well, plot twist: they're coming for the corner office instead. We're witnessing what economists are calling "The Great Decoupling" – basically, AI is doing to knowledge workers what the steam engine did to horse-drawn carriages. Except this time, it's happening at warp speed and affecting everyone from lawyers to software engineers. Here's the uncomfortable math: Corporate profits as a share of GDP just hit 11.55% (near record highs), while labor's slice of the pie dropped to 53.8% – the lowest since the 19...

When the people who know a company best are selling, it's worth paying attention. Three Nvidia executives have dumped over $105 million in stock since January 1st, and four billionaire fund managers just disclosed massive position cuts — all ahead of Wednesday's Q4 earnings report. CFO Colette Kress led the insider parade, unloading multiple batches across January and February totaling nearly $17 million. Executive VP Ajay Puri offloaded 400,000 shares worth roughly $73 million. Donald Robertson sold another 80,000 shares on New Year's Day. Across the board, Nvidia insiders have sold approxim...

Novo Nordisk had one job: prove its next-generation obesity drug could go toe-to-toe with Eli Lilly's juggernaut. It couldn't. Results from the Redefine 4 trial, released Monday morning, showed that Novo's CagriSema — a combination of semaglutide and cagrilintide — produced less weight loss than Eli Lilly's tirzepatide, sold as Zepbound for obesity and Mounjaro for Type 2 diabetes. Novo shares tanked 8.4% in premarket trading, adding to what's been a brutal stretch for the Danish pharma giant. This isn't just a clinical setback. It's a strategic one. CagriSema was supposed to be Novo's answe...

The biggest rotation in 16 years is happening and most retail investors are sleeping through it. U.S.-domiciled investors have yanked $75 billion from American equity products in the last six months — with $52 billion of that flowing out since January alone. That's the fastest exit in the first eight weeks of any year since at least 2010, according to LSEG/Lipper data. Where's the money going? Emerging markets sucked up $26 billion so far this year, with South Korea ($2.8 billion), Brazil ($1.2 billion), and Europe leading the charge. Bank of America's February fund manager survey showed the...

Well, well, well. Look who decided to show up to the 6,000 party again. The S&P 500 just closed at exactly 6,000 on Friday, and honestly, it feels like watching your friend finally get their life together after a really messy breakup with economic uncertainty. This is the first time we've seen this level since February, which in market years feels like approximately seventeen lifetimes ago. Between then and now, we've had tariff tantrums, inflation anxiety, and enough economic drama to fuel a Netflix series. The index took a 15% nosedive earlier this year, bottoming out around 4,983 in April....

Remember when your friend dropped $36,000 on a tiny Hermès bag and you thought they'd lost their mind? Plot twist: they might be the smartest investor you know. While you've been stress-watching your tech stocks do the cha-cha, luxury handbags have been quietly demolishing the S&P 500 like it's amateur hour. We're talking about the Mini Kelly II handbag returning over 300% from 2022 to 2025, starting at $9,200 and climbing to $36,980. Meanwhile, the S&P 500 managed a respectable but comparatively wimpy 43%. The iconic Birkin wasn't slacking either, appreciating 285% in the same period. That'...